ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,324 | -12.7% | 111,534 | +0.3% | 0.11% | -6.0% |
| Q2 2023 | $2,662 | -0.2% | 111,154 | -21.5% | 0.12% | -7.9% |
| Q1 2023 | $2,666 | -4.0% | 141,664 | -18.8% | 0.13% | -18.2% |
| Q4 2022 | $2,778 | -99.9% | 174,519 | -1.8% | 0.15% | -12.5% |
| Q3 2022 | $2,907,000 | +24.2% | 177,712 | +7.0% | 0.18% | 0.0% |
| Q2 2022 | $2,341,000 | -7.1% | 166,131 | +59.7% | 0.18% | +6.7% |
| Q1 2022 | $2,520,000 | +196.5% | 104,052 | +185.6% | 0.16% | +55.7% |
| Q4 2021 | $850,000 | +155.3% | 36,432 | +81.6% | 0.11% | +140.9% |
| Q3 2021 | $333,000 | -9.8% | 20,062 | +190.9% | 0.04% | -58.1% |
| Q4 2020 | $369,000 | +29.5% | 6,897 | 0.0% | 0.10% | +16.7% |
| Q3 2020 | $285,000 | -50.8% | 6,897 | -42.2% | 0.09% | -54.3% |
| Q2 2020 | $579,000 | -41.9% | 11,937 | -49.4% | 0.20% | -53.1% |
| Q1 2020 | $997,000 | +276.2% | 23,609 | +220.3% | 0.42% | +324.2% |
| Q3 2019 | $265,000 | – | 7,370 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |